Analysts’ Viewpoint
Emergence of new variants of virus and rise in government support for the development and distribution of COVID-19 vaccines are estimated to fuel market statistics. Increase in demand for booster shots to maintain immunity against new variants of the virus is creating growth opportunities for market players. However, the COVID-19 vaccine market has presently entered a period of stabilization, owing to the rapid decline in cases and increase in rate of vaccination around the globe. COVID-19 vaccine market demand has declined significantly, as more than 70% of the global population has already been vaccinated to date.
In the long term, the industry may need to consider strategies for maintaining demand for vaccines, such as promoting the benefits of coronavirus vaccination for herd immunity, or developing new vaccines for other infectious diseases. Overall, the COVID-19 vaccine market has been highly profitable for pharmaceutical companies. Leading players should focus on distribution and inventory management and explore coronavirus vaccine market opportunities.
COVID-19 vaccines are medical products designed to protect individuals from the novel coronavirus (SARS-CoV-2) that causes COVID-19. The vaccines work by teaching the immune system to recognize and fight the virus, thereby reducing the risk of severe illness or death from COVID-19. Several different COVID-19 vaccines have been developed and authorized for emergency use around the world, including vaccines developed by Pfizer-BioNTech, Moderna, AstraZeneca-Oxford, Johnson & Johnson, and others. mRNA and viral vector vaccines are the major types of COVID vaccines. These vaccines use different technologies, such as messenger RNA (mRNA) and adenovirus vectors, to instruct the body to produce an immune response against the virus. Vaccines have undergone rigorous testing in clinical trials to ensure their safety and efficacy. Trials have shown that vaccines are highly effective at preventing severe illness and death caused by COVID-19, and they have been authorized for use by regulatory bodies around the world. Vaccines are being distributed globally to protect as many people as possible from the virus and to help bring an end to the pandemic.
The emergence of new variants of the virus is one of the significant COVID-19 vaccine market growth drivers. These variants have the potential to be more transmissible and/or more resistant to current vaccines, which means that people who have been vaccinated may not be fully protected against them. This is a significant concern for public health officials and healthcare providers, as it could lead to a resurgence of the pandemic. To address this issue, people who have been vaccinated may need to get booster shots or updated versions of the vaccine to maintain immunity against these new variants. This is projected to fuel COVID-19 vaccine market development in the near future.
Governments have invested large amounts of money in the development, testing, and distribution of vaccines to combat the pandemic. This investment has been crucial in speeding up the process of vaccine development, and ensuring that vaccines are made available to the public as quickly as possible.
Pharmaceutical companies also invested heavily in the development and distribution of vaccines. These companies have invested in R&D to create new vaccines and booster shots, and have also invested in manufacturing facilities to produce these vaccines on a large scale.
Furthermore, the demand for vaccines is expected to remain high in the near future, as people are getting vaccinated to prevent the resurgence of COVID-19.
mRNA vaccines have been proven to be highly effective at triggering an immune response, with some achieving efficacy rates upwards of 95%. These vaccines are relatively easy to develop compared to other types of vaccines. mRNA vaccines do not require the use of a live virus, as is the case with viral vector vaccines. This means that mRNA vaccines can be produced faster and with fewer resources. As a result, mRNA vaccines are gaining popularity among end-users.
mRNA vaccines also have the advantage of being relatively stable, meaning they can be stored at a lower temperature than other types of COVID-19 vaccines. This makes them easier to transport, store, and distribute.
In terms of distribution channel, the government entities segment is anticipated to lead the global COVID-19 vaccine industry during the forecast period.
Governments are usually the primary providers of healthcare services in several countries. Moreover, government entities often have the resources and infrastructure to support large-scale vaccine distribution campaigns. Furthermore, governments are often responsible for the purchase, distribution, and administration of vaccine doses. Government bodies ensure that there is an adequate supply of vaccines for their citizens.
Government entities have made considerable investments to ramp up production and distribution of COVID-19 vaccines, and have coordinated with private companies and other entities to ensure that their citizens have access to the necessary doses. Several governments have created special programs to ensure that vulnerable populations have access to the vaccine. All these factors are positively impacting the COVID-19 vaccine market share.
In terms of age group, the global COVID-19 vaccine market has been segmented into 12 to 18 and above 18. The above 18 segment is likely to dominate the market during the forecast period. The adult population is more likely to get vaccinated than the younger population in the near future, as adults can easily understand the importance of vaccination.
The adult population is much larger than the younger population. According to the World Population Review of 2020, the population of adults aged 18 and above is around 4.6 billion, whereas the population of children aged 12 to 18 is around 1.2 billion. Vaccines for individuals 12 to 18 years of age are not readily available. This drives the segment.
In the U.S., the Pfizer-BioNTech vaccine was the first vaccine to be approved, and it was only approved for people aged 16 and above. Likewise, the Moderna vaccine was approved for those aged 18 and above.
North America is projected to dominate the global market during the forecast period. Increase in presence of major pharmaceutical companies and advanced healthcare infrastructure in the U.S. is fueling market progress.
Europe is expected to be the second-largest regional market for COVID-19 vaccines in the next few years, owing to the presence of well-developed healthcare infrastructure and rise in availability of skilled resources to manufacture vaccines.
In Asia Pacific, increase in government support to develop COVID-19 vaccines and the presence of the world's largest vaccine manufacturers, such as the Serum Institute of India and BioNTech, are driving the market.
Companies operating in the global market are focusing on strategies such as product launches, divestiture, mergers & acquisitions (M&A), and partnerships to strengthen their position in the market.
Some of the prominent COVID-19 vaccine manufacturers are Pfizer-BioNTech, Moderna, AstraZeneca, Johnson & Johnson, Sinovac, Sinopharm, Bharat Biotech, Serum Institute of India, Novavax, Gamaleya Research Institute, CanSino Biologics, CureVac, GlaxoSmithKline and Sanofi-GSK.
The global COVID-19 vaccine market report profiles key players based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
|
Attribute |
Detail |
|
Market Size Value in 2021 |
US$ 92.6 Bn |
|
Market Forecast Value in 2031 |
More than US$ 9.9 Bn |
|
Compound Annual Growth Rate (CAGR) |
-13.6% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2021 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global market was valued at US$ 92.6 Bn in 2021
It is projected to reach more than US$ 9.9 Bn by 2031
The CAGR is anticipated to be -13.6% from 2022 to 2031
Emergence of new variants of the virus and increase in investment in development and distribution of vaccines by several governments and pharmaceutical companies
The mRNA segment held the largest share in 2021
North America is likely to account for major share during the forecast period
Pfizer-BioNTech, Moderna, AstraZeneca, Johnson & Johnson, Sinovac, Sinopharm, Bharat Biotech, Serum Institute of India, Novavax, Gamaleya Research Institute, CanSino Biologics, CureVac, GlaxoSmithKline, and Sanofi-GSK.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global COVID-19 Vaccine Market
4. Market Overview
4.1. Introduction
4.1.1. COVID-19 vaccine Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global COVID-19 Vaccine Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Market Outlook
5.1. Disease incidence and prevalence across the globe
5.2. Analysis of COVID-19 vaccination across the globe
5.3. Regulatory scenario across the globe/key countries
6. Global COVID-19 Vaccine Market Analysis and Forecast, by Vaccine Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Vaccine Type, 2017–2031
6.3.1. mRNA
6.3.2. Viral Vector Vaccines
6.3.2.1. Inactivated Virus Vaccines
6.3.2.2. Adenovirus Vaccines
6.3.2.3. Others
6.3.3. Others
6.4. Market Attractiveness, by Vaccine Type
7. Global COVID-19 Vaccine Market Analysis and Forecast, by Age Group
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Age Group, 2017–2031
7.3.1. 12 to 18
7.3.2. Above 18
7.4. Market Attractiveness, by Age Group
8. Global COVID-19 Vaccine Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Government Entities
8.3.2. Hospitals and Clinics
8.3.3. Others
8.4. Market Attractiveness, by Distribution Channel
9. Global COVID-19 Vaccine Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness, by Country/Region
10. North America COVID-19 Vaccine Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Vaccine Type, 2017–2031
10.2.1. mRNA
10.2.2. Viral Vector Vaccines
10.2.2.1. Inactivated Virus Vaccines
10.2.2.2. Adenovirus Vaccines
10.2.2.3. Others
10.2.3. Others
10.3. Market Value Forecast, by Age Group, 2017–2031
10.3.1. 12 to 18
10.3.2. Above 18
10.4. Market Value Forecast, by Distribution Channel, 2017–2031
10.4.1. Government Entities
10.4.2. Hospitals and Clinics
10.4.3. Others
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Vaccine Type
10.6.2. By Age Group
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe COVID-19 Vaccine Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Vaccine Type , 2017–2031
11.2.1. mRNA
11.2.2. Viral Vector Vaccines
11.2.2.1. Viral Vector Vaccines
11.2.2.2. Adenovirus Vaccines
11.2.2.3. Others
11.2.3. Others
11.3. Market Value Forecast, by Age Group, 2017–2031
11.3.1. 12 to 18
11.3.2. Above 18
11.4. Market Value Forecast, by Distribution Channel, 2017–2031
11.4.1. Government Entities
11.4.2. Hospitals and Clinics
11.4.3. Others
11.5. Market Value Forecast, by Country, 2017–2031
11.5.1. U.K.
11.5.2. Germany
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Vaccine Type
11.6.2. By Age Group
11.6.3. By Distribution Channel
11.6.4. By Country
12. Asia Pacific COVID-19 Vaccine Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Vaccine Type, 2017–2031
12.2.1. mRNA
12.2.2. Viral Vector Vaccines
12.2.2.1. Inactivated Virus Vaccines
12.2.2.2. Adenovirus Vaccines
12.2.2.3. Others
12.2.3. Others
12.3. Market Value Forecast, by Age Group, 2017–2031
12.3.1. 12 to 18
12.3.2. Above 18
12.4. Market Value Forecast, by Distribution Channel, 2017–2031
12.4.1. Government Entities
12.4.2. Hospitals and Clinics
12.4.3. Others
12.5. Market Value Forecast, by Country, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Vaccine Type
12.6.2. By Age Group
12.6.3. By Distribution Channel
12.6.4. By Country
13. Latin America COVID-19 Vaccine Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Vaccine Type, 2017–2031
13.2.1. mRNA
13.2.2. Viral Vector Vaccines
13.2.2.1. Inactivated Virus Vaccines
13.2.2.2. Adenovirus Vaccines
13.2.2.3. Others
13.2.3. Others
13.3. Market Value Forecast, by Age Group, 2017–2031
13.3.1. 12 to 18
13.3.2. Above 18
13.4. Market Value Forecast, by Distribution Channel, 2017–2031
13.4.1. Government Entities
13.4.2. Hospitals and Clinics
13.4.3. Others
13.5. Market Value Forecast, by Country, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Vaccine Type
13.6.2. By Age Group
13.6.3. By Distribution Channel
13.6.4. By Country
14. Middle East & Africa COVID-19 Vaccine Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Vaccine Type, 2017–2031
14.2.1. mRNA
14.2.1.1. Inactivated Virus Vaccines
14.2.1.2. Adenovirus Vaccines
14.2.1.3. Others
14.2.2. Viral Vector Vaccines
14.2.3. Others
14.3. Market Value Forecast, by Age Group, 2017–2031
14.3.1. 12 to 18
14.3.2. Above 18
14.4. Market Value Forecast, by Distribution Channel, 2017–2031
14.4.1. Government Entities
14.4.2. Hospitals and Clinics
14.4.3. Others
14.5. Market Value Forecast, by Country, 2017–2031
14.5.1. GCC countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Vaccine Type
14.6.2. By Age Group
14.6.3. By Distribution Channel
14.6.4. By Country
15. Competition Landscape
15.1. Market Player – Competition Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis by Company (2021)
15.3. Company Profiles
15.3.1. Pfizer-BioNTech
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Vaccine Type Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Moderna
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Vaccine Type Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. AstraZeneca
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Vaccine Type Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Johnson & Johnson
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Vaccine Type Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Sinovac
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Vaccine Type Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Sinopharm
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Vaccine Type Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. Bharat Biotech
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Vaccine Type Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Serum Institute of India
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Vaccine Type Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Novavax
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Vaccine Type Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview
15.3.10. Gamaleya Research Institute
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Vaccine Type Portfolio
15.3.10.3. Financial Overview
15.3.10.4. SWOT Analysis
15.3.10.5. Strategic Overview
15.3.11. CanSino Biologics
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Vaccine Type Portfolio
15.3.11.3. Financial Overview
15.3.11.4. SWOT Analysis
15.3.11.5. Strategic Overview
15.3.12. CureVac
15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.12.2. Vaccine Type Portfolio
15.3.12.3. Financial Overview
15.3.12.4. SWOT Analysis
15.3.12.5. Strategic Overview
15.3.13. GlaxoSmithKline
15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.13.2. Vaccine Type Portfolio
15.3.13.3. Financial Overview
15.3.13.4. SWOT Analysis
15.3.13.5. Strategic Overview
15.3.14. Sanofi-GSK
15.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.14.2. Vaccine Type Portfolio
15.3.14.3. Financial Overview
15.3.14.4. SWOT Analysis
15.3.14.5. Strategic Overview
List of Tables
Table 01: Global COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Vaccine Type, 2017–2031
Table 02: Global COVID-19 Vaccine Market Value (US$ Mn) Forecast, by mRNA, 2017–2031
Table 03: Global COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Viral Vector Vaccines, 2017–2031
Table 04: Global COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Age Group, 2017–2031
Table 05: Global COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 06: Global COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 07: North America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Vaccine Type, 2017–2031
Table 08: North America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by mRNA, 2017–2031
Table 09: North America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Viral Vector Vaccines, 2017–2031
Table 10: North America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Age Group, 2017–2031
Table 11: North America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 12: North America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 13: Europe COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Vaccine Type , 2017–2031
Table 14: Europe COVID-19 Vaccine Market Value (US$ Mn) Forecast, by mRNA, 2017–2031
Table 15: Europe COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Viral Vector Vaccines, 2017–2031
Table 16: Europe COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Age Group, 2017–2031
Table 17: Europe COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 18: Europe COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031
Table 19: Asia Pacific COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Vaccine Type, 2017–2031
Table 20: Asia Pacific COVID-19 Vaccine Market Value (US$ Mn) Forecast, by mRNA, 2017–2031
Table 21: Asia Pacific COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Viral Vector Vaccines, 2017–2031
Table 22: Asia Pacific COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Age Group, 2017–2031
Table 23: Asia Pacific COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 24: Asia Pacific COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031
Table 25: Latin America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Vaccine Type, 2017–2031
Table 26: Latin America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by mRNA, 2017–2031
Table 27: Latin America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Viral Vector Vaccines, 2017–2031
Table 28: Latin America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Age Group, 2017–2031
Table 29: Latin America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 30: Latin America COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031
Table 31: Middle East & Africa COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Vaccine Type, 2017–2031
Table 32: Middle East & Africa COVID-19 Vaccine Market Value (US$ Mn) Forecast, by mRNA, 2017–2031
Table 33: Middle East & Africa COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Viral Vector Vaccines, 2017–2031
Table 34: Middle East & Africa COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Age Group, 2017–2031
Table 35: Middle East & Africa COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 36: Middle East & Africa COVID-19 Vaccine Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031
List of Figures
Figure 01: Global COVID-19 Vaccine Market
Figure 02: Global COVID-19 Vaccine Market Size (US$ Mn) Forecast, 2017–2031
Figure 03: Market Value Share, by Vaccine Type (2021)
Figure 04: Market Value Share, by Age Group (2021)
Figure 05: Market Value Share, by Distribution Channel (2021)
Figure 06: Market Value Share, by Region (2021)
Figure 07: Global COVID-19 Vaccine Market Value Share, by Vaccine Type, 2021 and 2031
Figure 08 Global COVID-19 Vaccine Market Attractiveness, by Vaccine Type , 2021–2031
Figure 09: Global COVID-19 Vaccine Market Value Share, by Age Group, 2021 and 2031
Figure 10: Global COVID-19 Vaccine Market Attractiveness, by Age Group, 2021–2031
Figure 11: Global COVID-19 Vaccine Market Value Share, by Distribution Channel, 2021 and 2031
Figure 12: Global COVID-19 Vaccine Market Attractiveness, by Distribution Channel, 2021–2031
Figure 13: Global COVID-19 Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2031
Figure 14: Global COVID-19 Vaccine Market Value Share, by Region, 2021–2031
Figure 15: Global COVID-19 Vaccine Market Attractiveness, by Region, 2021–2031
Figure 16: North America COVID-19 Vaccine Market Value Share, by Vaccine Type, 2021 and 2031
Figure 17: North America COVID-19 Vaccine Market Attractiveness, by Vaccine Type , 2021–2031
Figure 18: North America COVID-19 Vaccine Market Value Share, by Age Group, 2021 and 2031
Figure 19: North America COVID-19 Vaccine Market Attractiveness, by Age Group, 2021–2031
Figure 20: North America COVID-19 Vaccine Market Value Share, by Distribution Channel, 2021 and 2031
Figure 21: North America COVID-19 Vaccine Market Attractiveness, by Distribution Channel, 2021–2031
Figure 22: North America COVID-19 Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2031
Figure 23: North America COVID-19 Vaccine Market Value Share, by Country, 2021–2031
Figure 24: North America COVID-19 Vaccine Market Attractiveness, by Country, 2021–2031
Figure 25: Europe COVID-19 Vaccine Market Value Share, by Vaccine Type, 2021 and 2031
Figure 26: Europe COVID-19 Vaccine Market Attractiveness, by Vaccine Type , 2021–2031
Figure 27: Europe COVID-19 Vaccine Market Value Share, by Age Group, 2021 and 2031
Figure 28: Europe COVID-19 Vaccine Market Attractiveness, by Age Group, 2021–2031
Figure 29: Europe COVID-19 Vaccine Market Value Share, by Distribution Channel, 2021 and 2031
Figure 30: Europe COVID-19 Vaccine Market Attractiveness, by Distribution Channel, 2021–2031
Figure 31: Europe COVID-19 Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2031
Figure 32: Europe COVID-19 Vaccine Market Value Share, by Country/Sub-Region, 2021–2031
Figure 33: Europe COVID-19 Vaccine Market Attractiveness, by Country/Sub-Region, 2021–2031
Figure 34: Asia Pacific COVID-19 Vaccine Market Value Share, by Vaccine Type, 2021 and 2031
Figure 35: Asia Pacific COVID-19 Vaccine Market Attractiveness, by Vaccine Type , 2021–2031
Figure 36: Asia Pacific COVID-19 Vaccine Market Value Share, by Age Group, 2021 and 2031
Figure 37: Asia Pacific COVID-19 Vaccine Market Attractiveness, by Age Group, 2021–2031
Figure 38: Asia Pacific COVID-19 Vaccine Market Value Share, by Distribution Channel, 2021 and 2031
Figure 39: Asia Pacific COVID-19 Vaccine Market Attractiveness, by Distribution Channel, 2021–2031
Figure 40: Asia Pacific COVID-19 Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2031
Figure 41: Asia Pacific COVID-19 Vaccine Market Value Share, by Country/Sub-Region, 2021–2031
Figure 42: Asia Pacific COVID-19 Vaccine Market Attractiveness, by Country/Sub-Region, 2021–2031
Figure 43: Latin America COVID-19 Vaccine Market Value Share, by Vaccine Type, 2021 and 2031
Figure 44: Latin America COVID-19 Vaccine Market Attractiveness, by Vaccine Type , 2021–2031
Figure 45: Latin America COVID-19 Vaccine Market Value Share, by Age Group, 2021 and 2031
Figure 46: Latin America COVID-19 Vaccine Market Attractiveness, by Age Group, 2021–2031
Figure 47: Latin America COVID-19 Vaccine Market Value Share, by Distribution Channel, 2021 and 2031
Figure 48: Latin America COVID-19 Vaccine Market Attractiveness, by Distribution Channel, 2021–2031
Figure 49: Latin America COVID-19 Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2031
Figure 50: Latin America COVID-19 Vaccine Market Value Share, by Country/Sub-Region, 2021–2031
Figure 51: Latin America COVID-19 Vaccine Market Attractiveness, by Country/Sub-Region, 2021–2031
Figure 52: Middle East & Africa COVID-19 Vaccine Market Value Share, by Vaccine Type, 2021 and 2031
Figure 53: Middle East & Africa COVID-19 Vaccine Market Attractiveness, by Vaccine Type, 2021–2031
Figure 54: Middle East & Africa COVID-19 Vaccine Market Value Share, by Age Group, 2021 and 2031
Figure 55: Middle East & Africa COVID-19 Vaccine Market Attractiveness, by Age Group, 2021–2031
Figure 56: Middle East & Africa COVID-19 Vaccine Market Value Share, by Distribution Channel, 2021 and 2031
Figure 57: Middle East & Africa COVID-19 Vaccine Market Attractiveness, by Distribution Channel, 2021–2031
Figure 58: Middle East & Africa COVID-19 Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2031
Figure 59: Middle East & Africa COVID-19 Vaccine Market Value Share, by Country/Sub-Region, 2021–2031
Figure 60: Middle East & Africa COVID-19 Vaccine Market Attractiveness, by Country/Sub-Region, 2021–2031
Figure 61: Global COVID-19 Vaccine Market Share Analysis, by Company, 2021 (Estimated)
Figure 62: Global COVID-19 Vaccine Market Performance, by Company, 2021
Figure 63: Competition Matrix
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
COVID-19 Vaccine Market
*86 figures and 60 tables includes